Greenwich LifeSciences, Inc. (GLSI)


+0.33 (+2.83%)
Symbol GLSI
Price $11.98
Beta 3.195
Volume Avg. 0.01M
Market Cap 153.921M
Shares () -
52 Week Range 7.58-21.5
1y Target Est -
DCF Unlevered GLSI DCF ->
DCF Levered GLSI LDCF ->
ROE -78.09% Strong Sell
ROA -94.74% Strong Sell
Operating Margin -
Debt / Equity -
P/E -17.11 Strong Sell
P/B 17.39 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest GLSI news

Mr. Snehal S. Patel
NASDAQ Capital Market

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.